Steven Weber - 14 Jul 2025 Form 4 Insider Report for PULSE BIOSCIENCES, INC. (PLSE)

Reporting relationship: Principal Accounting Officer
Issuer ticker: PLSE
Reported as of: 14 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jul 2025, 18:26:07 UTC
Prior SEC filing: 20 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Kenneth B. Stratton, as Attorney-in-Fact

Key filing fact

Steven Weber filed Form 4 for PULSE BIOSCIENCES, INC. (PLSE) on 16 Jul 2025.

Key facts

This page summarizes Steven Weber's Form 4 filing for PULSE BIOSCIENCES, INC. (PLSE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Jul 2025, 18:26.

Change

Previous filing in this sequence was filed on 20 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001844594 Primary reporting owner

Weber Steven

Relationship: Principal Accounting Officer
Address: C/O PULSE BIOSCIENCES, INC., 3957 POINT EDEN WAY, HAYWARD
Signature: /s/ Kenneth B. Stratton, as Attorney-in-Fact
Signature date: 16 Jul 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PLSE transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +55,000
Change %
Price: $0.000000
Shares after: 55,000
Date: 14 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 55,000
Exercise price: $16.03
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Half of the shares subject to the option will vest in equal installments on the first, second, third, and fourth anniversaries of the grant date and the remaining shares subject to the option will vest in equal tranches upon the achievement of four performance-based vesting criteria tied to the Issuer's market capitalization ranging from $1.5 billion to $4.0 billion, in all cases, subject to the Reporting Person's continued service through each vesting milestone.